---
document_datetime: 2025-11-23 08:01:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/yondelis-0.html
document_name: yondelis-0.html
version: success
processing_time: 0.0416232
conversion_datetime: 2025-12-28 17:50:08.900888
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Yondelis

[RSS](/en/individual-human-medicine.xml/66974)

##### Refused

This medicine has been refused authorisation

trabectedin

Medicine

Human

Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [More information on Yondelis](#more-information-on-yondelis-838)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 July 2003 the Committee for Proprietary Medicinal Products (CPMP) adopted a negative opinion, recommending not to grant a marketing authorisation for the medicinal product Yondelis, 0.25 mg and 1 mg, powder for concentrate for solution for infusion intended for patients with advanced soft tissue sarcoma (STS), having failed anthracyclines and ifosfamide, or having failed ifosfamide and unsuitable to receive anthracyclines. Yondelis was designated as an orphan medicinal product on 30 May 2001 (EU/3/01/039). The applicant for this medicinal product is Pharma Mar S.A.

CHMP summary of negative opinion for Yondelis

Adopted

Reference Number: CPMP/5706/03

English (EN) (312.9 KB - PDF)

**First published:** 20/11/2003

**Last updated:** 20/11/2003

[View](/en/documents/smop-initial/chmp-summary-negative-opinion-yondelis_en.pdf)

## Product details

Name of medicine Yondelis Active substance trabectedin International non-proprietary name (INN) or common name trabectedin Therapeutic area (MeSH) Sarcoma Anatomical therapeutic chemical (ATC) code L01CX01

### Pharmacotherapeutic group

Antineoplastic agents

## Application details

EMA product number EMEA/H/C/000464 Marketing authorisation applicant Pharma Mar S.A. Opinion adopted 20/11/2003 Refusal of marketing authorisation 07/09/2004

#### More information on Yondelis

The European Commission initially refused the marketing authorisation for this medicine. Following a later application by the company, the European Commission [granted a marketing authorisation](/en/medicines/human/EPAR/yondelis) for the medicine.

**This page was last updated on** 20/11/2003

## Share this page

[Back to top](#main-content)